Stay updated on Pembrolizumab in SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in SCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:28:41.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a potential update or revision in the study details related to the efficacy of pembrolizumab in patients with small cell lung cancer (SCLC) and its interaction with chemotherapy and radiation therapy.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:04.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of 'Participation Criteria,' explaining that researchers look for people who fit specific eligibility criteria, such as general health condition or prior treatments. The new text also provides an example of eligibility criteria for a clinical study on small cell lung carcinoma.
    Difference
    55%
    Check dated 2024-05-22T20:30:31.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:32:19.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in SCLC Clinical Trial page.